Search

Your search keyword '"Piccaluga, PP."' showing total 446 results
Start Over Author "Piccaluga, PP."
446 results on '"Piccaluga, PP."'

1. First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation

Author

Piccaluga PP, Paolini S, Bertuzzi C, De Leo A, and Rosti G

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Pier Paolo Piccaluga,* Stefania Paolini,* Clara Bertuzzi, Antonio De Leo, Gianantonio RostiHematopathology and Hematology Sections, Department of Hematology and Oncological Sciences, "L and A Seràgnoli", S Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy*These authors contributed equally to this workAbstract: The therapeutic landscape of chronic myeloid leukemia (CML) has changed dramatically in the last decade. In particular, the availability of imatinib mesylate, a tyrosine kinase inhibitor targeting BCR-ABL, has led to profound and durable remissions in the majority of patients. However, a couple of issues have emerged and partially obscured this scenario. First, it has become clear that a significant proportion of patients either present with primary resistance to imatinib or develop secondary resistance sooner or later during treatment. Second, although the drug is generally well tolerated, a percentage of patients eventually cease treatment because of toxicity. Bearing this in mind, second-generation tyrosine kinase inhibitors have been introduced, including nilotinib. Phase I and II studies indicate remarkable activity for this compound in CML cases resistant to imatinib, including some of those carrying BCR-ABL1 mutants. More recently, two Phase II studies and a III randomized Phase clinical trial demonstrated the superiority of nilotinib compared with imatinib in terms of complete cytogenetic and major molecular responses, which are two relevant surrogate measures of long-term survival in CML. In this paper, we review the most relevant data on nilotinib as first-line treatment for CML, and discuss the rationale for its routine use, as well as some possible future perspectives for CML patients.Keywords: chronic myeloid leukemia, nilotinib, targeted therapy, BCR-ABL1

Published
2012

4. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients

Author

Visani, G, Bernasconi, P, Boni, M, Castoldi, GL, Ciolli, S, Clavio, M, Cox, MC, Cuneo, A, Del Poeta, G, Dini, D, Falzetti, D, Fanin, R, Gobbi, M, Isidori, A, Leoni, F, Liso, V, Malagola, M, Martinelli, G, Mecucci, C, Piccaluga, PP, Petti, MC, Rondelli, R, Russo, D, Sessarego, M, Specchia, G, Testoni, N, Torelli, G, Mandelli, F, and Tura, S

Published
2001
Full Text
View/download PDF

8. IKZF1 (IKAROS) deletions represent a poor prognostic marker in BCR-ABL1 positive acute lymphoblastic leukaemia patients: a GIMEMA ALL WP report: O133

Author

Iacobucci, I., Lonetti, A., Ferrari, A., Vignetti, M., Storlazzi, C. T., Paoloni, F., Cilloni, D., Soverini, S., Vitale, A., Chiaretti, S., Cimino, G., Astolfi, A., Testoni, N., Papayannidis, C., Paolini, S., Piccaluga, PP., Elia, L., Messa, F., DellʼAgnola, C., Cingarlini, S., Meloni, G., Leone, G., Amadori, S., Russo, D., Saglio, G., Pane, F., Baccarani, M., Foà, R., and Martinelli, G.

Published
2009

9. pH-positive acute lymphoblastic leukaemia is characterised by recurrent copy number anomalies in genes regulating the cell cycle and B-cell differentiation: O138

Author

Iacobucci, I., Ottaviani, E., Lonetti, A., Ferrari, A., Astolfi, A., Storlazzi, CT., Testoni, N., Paolini, S., Papayannidis, C., Cilloni, D., Messa, F., Soverini, S., Arruga, F., Pane, F., Vitale, A., Messina, M., Chiaretti, S., Piccaluga, PP., DellʼAgnola, C., Cingarlini, S., Foà, R., Baccarani, M., and Martinelli, G.

Published
2009

10. MINIMAL RESIDUAL DISEASE (MRD) EVALUATION IN LYMPHOMAS WITHIN THE FIL (FONDAZIONE ITALIANA LINFOMI) MRD NETWORK: INTER-LABORATORY REPRODUCIBILITY ON BORDERLINE SAMPLES

Author

Della Starza, I, Cavalli, M, De Novi, LA, Genuardi, E, Mantoan, B, Drandi, D, Monitillo, L, Ciabatti, E, Grassi, S, Gazzola, A, Mannu, C, Agostinelli, C, Piccaluga, PP, Galimberti, S, Guarini, A, Foa, R, Ladetto, M, Ferrero, S, Del Giudice, I, Della Starza, I, Cavalli, M, De Novi, LA, Genuardi, E, Mantoan, B, Drandi, D, Monitillo, L, Ciabatti, E, Grassi, S, Gazzola, A, Mannu, C, Agostinelli, C, Piccaluga, PP, Galimberti, S, Guarini, A, Foa, R, Ladetto, M, Ferrero, S, and Del Giudice, I

Subjects
MINIMAL RESIDUAL DISEASE (MRD), LYMPHOMAS
Published
2017

11. Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma

Author

FRANCO, Giovanni, GUARNOTTA, Carla, Piccaluga, PP, Boveri, E, GULINO, Alessandro, Fuligni, F, Rigoni, A, Porcasi, R, Buffa, S, Betto, E, FLORENA, Ada Maria, FRANCO, Vito, Iannitto, E, Arcaini, L, Pileri, SA, Pucillo, C, Colombo, MP, Sangaletti, S, TRIPODO, Claudio, Frossi, B, PORCASI, Rossana, Franco, G, Guarnotta, C, Frossi, Piccaluga, PP, Boveri, E, Gulino, A, Fuligni, F, Rigoni, A, Porcasi, R, Buffa, S, Betto, E, Florena, AM, Franco, V, Iannitto, E, Arcaini, L, Pileri, SA, Pucillo, C, Colombo, MP, Sangaletti, S, Tripodo, C, Franco, Giovanni, Guarnotta, Carla, Frossi, Barbara, Piccaluga, Pier Paolo, Boveri, Emanuela, Gulino, Alessandro, Fuligni, Fabio, Rigoni, Alice, Porcasi, Rossana, Buffa, Salvatore, Betto, Elena, Florena, Ada Maria, Franco, Vito, Iannitto, Emilio, Arcaini, Luca, Pileri, Stefano Aldo, Pucillo, Carlo, Colombo, Mario Paolo, Sangaletti, Sabina, and Tripodo, Claudio

Subjects
Male, Pathology, Biochemistry, Mice, Tumor Microenvironment, Mast Cell, Medicine, Mast Cells, Inflammation Mediator, Aged, 80 and over, Mice, Knockout, B-Lymphocytes, Mice, Inbred BALB C, Mesenchymal Stromal Cell, B-Lymphocyte, CD40 Antigen, Cell Differentiation, Hematology, Middle Aged, Prognosis, medicine.anatomical_structure, Disease Progression, Cytokines, Female, Inflammation Mediators, Clone (B-cell biology), Human, Adult, medicine.medical_specialty, Stromal cell, Prognosi, CD40 Ligand, Immunology, Disease-Free Survival, Animals, Humans, Splenic marginal zone lymphoma, CD40 Antigens, Cytokine, B cell, Aged, Cell Proliferation, Animal, business.industry, Mesenchymal stem cell, Mesenchymal Stem Cells, Lymphoma, B-Cell, Marginal Zone, Cell Biology, Genes, p53, medicine.disease, Lymphoma, Splenic marginal zone lymphoma, bone marrow microenvironment, CD40, Mast cell sarcoma, Bone marrow, business
Abstract

Splenic marginal zone lymphoma (SMZL) is a mature B-cell neoplasm characterized by rather indolent clinical course. However, nearly one third of patients experience a rapidly progressive disease with a dismal outcome. Despite the characterization of clone geneticsandthe recognition of deregulated immunologic stimulation in the pathogenesis of SMZL, little is known about microenvironment dynamics and their potential biological influence on disease outcome. Here we investigate the effect of stroma-intrinsic features on SMZL disease progression by focusing on the microenvironment of the bone marrow (BM), which represents an elective disease localization endorsing diagnostic and prognostic relevance. We show that the quality of the BM stromal meshwork of SMZL infiltrates correlates with time to progression. In particular, we describe the unfavorable prognostic influence of dense CD40 expression by BM stromal cells, which involves the contribution of CD40 ligand (CD40L)-expressing bystander mast cells infiltrating SMZL BM aggregates. The CD40/CD40L-assisted crosstalk between mesenchymal stromal cells and mast cells populating the SMZL microenvironment finds correlation in p53-/- mice developing SMZL and contributes to the engendering of detrimental proinflammatory conditions. Our study highlights a dynamic interaction, playing between nonneoplastic elements within the SMZL niche, toward disease progression. © 2014 by The American Society of Hematology.

Published
2014

14. Mesenchymal Stromal Cells interplay with Umbilical Cord Blood Hematopoietic Progenitor Cells for hematopoietic reconstitution. Co-culturing effects and Gene Expression Profiles

Author

Di Palma, A, Perucca, S, Piccaluga, Pp, Gemelli, C, Zoratti, Elisa, Bassi, Giulio, Giacopuzzi, E, Lojacono, A, Borsani, G, Tagliafico, E, Scupoli, Maria, Bernardi, Stefano, Zanaglio, C, Cattina, F, Cancelli, V, Malagola, M, Krampera, Mauro, Marini, M, Almici, C, Ferrari, S, and Russo, D.

Subjects
Transplantation, Oncology, Immunology, Hematology
Published
2016

16. The bone marrow stroma in hematological neoplasms-a guilty bystander

Author

TRIPODO, Claudio, FRANCO, Giovanni, Sangaletti, S, Piccaluga, PP, Prakash, S, Borrello, I, Orazi, A, Colombo, MP, Pileri, S.A., Tripodo, C, Sangaletti, S, Piccaluga, PP, Prakash, S, Franco, G, Borrello, I, Orazi, A, Colombo, MP, and Pileri, SA.

Subjects
hematological malignancies, bone marrow stroma
Abstract

In the setting of hematological neoplasms, changes in the bone marrow (BM) stroma might arise from pressure exerted by the neoplastic clone in shaping a supportive microenvironment, or from chronic perturbation of the BM homeostasis. Under such conditions, alterations in the composition of the BM stroma can be profound, and could emerge as relevant prognostic factors. In this Review, we delineate the multifaceted contribution of the BM stroma to the pathobiology of several hematological neoplasms, and discuss the impact of stromal modifications on the natural course of these diseases. Specifically, we highlight the involvement of BM stromal components in lymphoid and myeloid malignancies, and present the most relevant processes responsible for remodeling the BM stroma. The role of bystander BM stromal elements in the setting of hematological neoplasms is discussed, strengthening the rationale for treatment strategies that target the BM stroma.

Published
2011

17. Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience

Author

PAPAYANNIDIS, CRISTINA, IACOBUCCI, ILARIA, SOVERINI, SIMONA, LONETTI, ANNALISA, TESTONI, NICOLETTA, PAOLINI, STEFANIA, CASTAGNETTI, FAUSTO, ROSTI, GIANANTONIO, BACCARANI, MICHELE, MARTINELLI, GIOVANNI, Colarossi S, Gnani A, Amabile M, Ottaviani E, Abbenante M, Curti A, Lama B, Poerio A, Clissa C, Parisi S, Guadagnuolo V, Piccaluga PP, Papayannidis C, Iacobucci I, Soverini S, Colarossi S, Gnani A, Lonetti A, Testoni N, Amabile M, Ottaviani E, Abbenante M, Curti A, Paolini S, Lama B, Castagnetti F., Poerio A, Clissa C, Parisi S, Guadagnuolo V, Piccaluga PP, Rosti G, Baccarani M, and Martinelli G

Subjects
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Published
2009

18. PDGFR blockade is a rational and effective therapy for NPM-ALK\u2013driven lymphomas

Author

Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Hxf6fler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, and Kenner L

Published
2012

20. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition

Author

Sapienza, Mr, Fuligni, F, Agostinelli, C, Tripodo, C, Righi, S, Laginestra, Ma, Pileri, A, Mancini, M, Rossi, M, Ricci, F, Gazzola, A, Melle, F, Mannu, C, Ulbar, F, Arpinati, M, Paulli, M, Maeda, T, Gibellini, D, Pagano, Livio, Pimpinelli, N, Santucci, M, Cerroni, L, Croce, Cm, Facchetti, F, Piccaluga, Pp, Pileri, Sa, Pagano, Livio (ORCID:0000-0001-8287-928X), Sapienza, Mr, Fuligni, F, Agostinelli, C, Tripodo, C, Righi, S, Laginestra, Ma, Pileri, A, Mancini, M, Rossi, M, Ricci, F, Gazzola, A, Melle, F, Mannu, C, Ulbar, F, Arpinati, M, Paulli, M, Maeda, T, Gibellini, D, Pagano, Livio, Pimpinelli, N, Santucci, M, Cerroni, L, Croce, Cm, Facchetti, F, Piccaluga, Pp, Pileri, Sa, and Pagano, Livio (ORCID:0000-0001-8287-928X)

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease of controversial origin recently recognized as a neoplasm deriving from plasmacytoid dendritic cells (pDCs). Nevertheless, it remains an orphan tumor with obscure biology and dismal prognosis. To better understand the pathobiology of BPDCN and discover new targets for effective therapies, the gene expression profile (GEP) of 25 BPDCN samples was analyzed and compared with that of pDCs, their postulated normal counterpart. Validation was performed by immunohistochemistry (IHC), whereas functional experiments were carried out ex vivo. For the first time at the molecular level, we definitely recognized the cellular derivation of BPDCN that proved to originate from the myeloid lineage and in particular, from resting pDCs. Furthermore, thanks to an integrated bioinformatic approach we discovered aberrant activation of the NF-kB pathway and suggested it as a novel therapeutic target. We tested the efficacy of anti-NF-kB-treatment on the BPDCN cell line CAL-1, and successfully demonstrated by GEP and IHC the molecular shutoff of the NF-kB pathway. In conclusion, we identified a molecular signature representative of the transcriptional abnormalities of BPDCN and developed a cellular model proposing a novel therapeutic approach in the setting of this otherwise incurable disease.

Published
2014

22. Multicenter prospective clinical trial with low dose Gentuzumab-Ozogamicin plus fludarabine, Cytarabine, Idarubicin, (GO.FLAI) as induction therapy of CD33-positiveacute myeloid leukemia AML patients younger than 65 years

Author

Candoni, A, Martinelli, G, Gherlizoni, F, Papaynidis, C, Toffoletti, E, Simeone, E, Ottaviani, E, Gottardi, M, Iacobucci, I, Paolini, S, Michelutti, A, Lama, B, Calistri, E, Visani, G, Isidori, A, Piccaluga, Pp, Damiani, Daniela, Russo, D, and Fanin, R.

Published
2009

23. Molecular anatomy of peripheral T cell lymphomas

Author

Pellegrino, Elisa, Agnelli, L, Todoerti, K, Fornari, A, Novero, D, Cuccuru, G, Ferreri, C, Martinoglio, B, Medico, Enzo, Zamò, A, Facchetti, F, De Chiara, A, Ponzoni, M, Rosenwald, A, Müller Hermelink HK, De Wolf Peeters, C, Piccaluga, Pp, Pileri, S, Neri, A, Inghirami, Giorgio, and Piva, Roberto

Published
2009

27. Expression of spliced oncogenic Ikaros isoforms inPhiladelphia-positive acute lymphoblastic leukemia patients treated with tyrosinekinase inhibitors: implications for a new mechanism of resistance

Author

Iacobucci, I, Lonetti, A, Messa, F, Cilloni, Daniela, Arruga, F, Ottaviani, E, Paolini, S, Papayannidis, C, Piccaluga, Pp, Giannoulia, P, Soverini, S, Amabile, M, Poerio, A, Saglio, Giuseppe, Pane, F, Berton, G, Baruzzi, A, Vitale, A, Chiaretti, S, Perini, G, Foã, R, Baccarani, M, and Martinelli, G.

Published
2008

28. Genomic and functional approaches as powerful tools to stratify human T-cell lymphoproliferative disorders and to identify relevant tumorigenic culprits

Author

Piva, Roberto, Pellegrino, Elisa, Agnelli, L, Grosso, V, Tamagno, I, Ferrantino, L, Cagnoni, G, Fornari, A, Novero, D, Poli, V, Zamò, A, Chiosi, M, Rosenwald, A, Müller Hermelink HK, Vermi, W, Facchetti, F, Fulciniti, F, De Chiara, A, Ponzoni, M, Doglioni, C, Piccaluga, Pp, Pileri, S, De Wolf Peeters, C, Neri, A, and Inghirami, Giorgio

Published
2008

29. Identification of different Ikaros cDNAtranscripts in Philadelphia-positive adult acute lymphoblastic leukemia by ahigh-throughput capillary electrophoresis sizing method

Author

Iacobucci, I, Lonetti, A, Cilloni, Daniela, Messa, F, Ferrari, A, Zuntini, R, Ferrari, S, Ottaviani, E, Arruga, F, Paolini, S, Papayannidis, C, Piccaluga, Pp, Soverini, S, Saglio, Giuseppe, Pane, F, Baruzzi, A, Vignetti, M, Berton, G, Vitale, A, Chiaretti, S, Mã¼schen, M, Foã, R, Baccarani, M, and Martinelli, G.

Published
2008

40. Correlation between the response to induction treatment, including or not fludarabine and the MDR phenotype in newly diagnosed acute myeloid leukemia patients. Results of a case-control study

Author

Malagola, Michele, Damiani, D, Martinelli, G, Michelutti, A, Cesana, Bruno Mario, Candoni, A, Geromin, A, Piccaluga, Pp, Testoni, N, DE VIVO, A, Gobbi, M, Pierri, I, Lauria, F, Bocchia, M, Zaccaria, A, Zuffa, E, Mazza, P, Piccolo, G, Gugliotta, L, Bonini, A, Visani, G, Skert, C, Fil, C, Bergonzi, C, Roccaro, A. M., Fanin, R, Baccarani, M, and Russo, Domenico

Published
2006

43. Multicenter phase III trial on fludarabine, ara-C and idarubicine (FLAI) versus idarubicine, ara-C and etoposide (ICE) for induction treatment of younger newly diagnosed AML patients

Author

Russo, Domenico, Malagola, Michele, Martinelli, G, Piccaluga, Pp, Damiani, D, Candoni, A, Michelutti, A, Castelli, M, Testoni, N, Ottaviani, E, De Vivo, A, Rondoni, M, Pricolo, G, Mazza, P, Zuffa, E, Zaccaria, A, Raspadori, D, Bocchia, M, Lauria, F, Bonini, A, Avanzini, P, Gugliotta, L, Visani, G, Fanin, R, and Baccarani, M.

Published
2005

48. Idiopathic hypereosinphilic synndrome (HES) with FIP1L1-PDGFR-alpha rearrangement can be effectively treated with imatinib

Author

Martinelli, G, Cilloni, D, Ottaviani, E, Malagola, Michele, Messa, F, Rondoni, M, Bosi, C, Gottardi, E, Rosti, G, Ricci, P, Gaitani, S, Pane, F, Testoni, N, Mecucci, C, Soverini, S, Piccaluga, Pp, Amabile, M, Tiribelli, M, Zaccaria, A, Grafone, T, De Vivo, A, Pileri, S, Fattori, Pp, Bocchia, M, Serra, A, Maurillo, L, Fanin, R, Cross, N, Merante, S, Cazzola, M, Alimena, G, Frassoni, F, Galieni, P, Russo, Domenico, Gobbi, M, Gugliotta, L, Lauria, F, Mazza, P, Ferrara, F, Gherlinzoni, F, Leoni, P, Pellegrino, M, Baccarani, M, and Saglio, G.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results